AI-Driven Genomics and CRISPR: New Era of Biological Innovation

Recent market developments highlight AI's impact on genomics and gene editing, with implications for human health and biologically assembled materials. Companies like Illumina, Guardant Health, and Recursion Pharmaceuticals are driving innovation through AI-driven pattern recognition, gene discovery, editing, and biological manufacturing. Recursion Pharmaceuticals' platform uses machine learning to analyze biological responses at scale, reducing development time and cost.